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Abstract
IMPORTANCE—For patients with limited prognosis, some medication risks may outweigh the 
benefits, particularly when benefits take years to accrue; statins are one example. Data are lacking 
regarding the risks and benefits of discontinuing statin therapy for patients with limited life 
expectancy.
OBJECTIVE—To evaluate the safety, clinical, and cost impact of discontinuing statin 
medications for patients in the palliative care setting.
DESIGN, SETTING, AND PARTICIPANTS—This was a multicenter, parallel-group, 
unblinded, pragmatic clinical trial. Eligibility included adults with an estimated life expectancy of 
between 1 month and 1 year, statin therapy for 3 months or more for primary or secondary 
prevention of cardiovascular disease, recent deterioration in functional status, and no recent active 
cardiovascular disease. Participants were randomized to either discontinue or continue statin 
therapy and were monitored monthly for up to 1 year. The study was conducted from June 3, 
2011, to May 2, 2013. All analyses were performed using an intent-to-treat approach.
INTERVENTIONS—Statin therapy was withdrawn from eligible patients who were randomized 
to the discontinuation group. Patients in the continuation group continued to receive statins.
MAIN OUTCOMES AND MEASURES—Outcomes included death within 60 days (primary 
outcome), survival, cardiovascular events, performance status, quality of life (QOL), symptoms, 
number of nonstatin medications, and cost savings.
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RESULTS—A total of 381 patients were enrolled; 189 of these were randomized to discontinue 
statins, and 192 were randomized to continue therapy. Mean (SD) age was 74.1 (11.6) years, 
22.0% of the participants were cognitively impaired, and 48.8% had cancer. The proportion of 
participants in the discontinuation vs continuation groups who died within 60 days was not 
significantly different (23.8% vs 20.3%; 90% CI, −3.5% to 10.5%; P = .36) and did not meet the 
noninferiority end point. Total QOL was better for the group discontinuing statin therapy (mean 
McGill QOL score, 7.11 vs 6.85; P = .04). Few participants experienced cardiovascular events (13 
in the discontinuation group vs 11 in the continuation group). Mean cost savings were $3.37 per 
day and $716 per patient.
CONCLUSIONS AND RELEVANCE—This pragmatic trial suggests that stopping statin 
medication therapy is safe and may be associated with benefits including improved QOL, use of 
fewer nonstatin medications, and a corresponding reduction in medication costs. Thoughtful 
patient-provider discussions regarding the uncertain benefit and potential decrement in QOL 
associated with statin continuation in this setting are warranted.
TRIAL REGISTRATION—clinicaltrials.gov Identifier: NCT01415934
Safe and effective use of medicines includes medication selection and dosing for a targeted 
indication, monitoring for benefits and harms, and discontinuation when appropriate. Data 
from clinical trials guide the initiation of long-term medication therapy for primary or 
secondary prevention of cardiovascular disease but rarely define the timing, safety, or risks 
of discontinuing the agents. As a result, the number of medications often accumulates.1,2
This issue is particularly salient in the setting of advanced life-limiting illness, when patients 
face escalating numbers of medications prescribed for common comorbidities (eg, 
antihypertensives), disease-specific medications (eg, antineoplastics), and symptom 
palliation (eg, opioids).2,3 In the last year of life, the number of medicines increases by 
50%.1 In addition, the effects of advanced disease may alter a patient’s metabolism of 
medications and increase the risk of adverse effects. Dysphagia and anorexia increase the 
burden of taking multiple pills.2
Many physicians advocate discontinuing unnecessary medicines in the setting of advanced 
life-limiting illness3 to reduce adverse effects, pill burden, and medication costs while 
potentially enhancing quality of life (QOL) and possibly survival.3–5 However, the choice of 
which medicines to discontinue, as well as timing and safety, is unclear.2,6,7
Statin therapy is commonly considered for discontinuation in the setting of advanced life-
limiting illness.8 More than 25% of Medicare beneficiaries receive statin therapy.9 When 
this drug class is prescribed for primary prevention of cardiovascular disease, benefits 
accrue after 2 years.10,11 In the presence of cardiovascular disease (secondary prevention), 
benefits relate to both long-term lowering of lipid levels plus shorter-term effects on 
inflammation and endothelial function.12 The main adverse effects of statins are 
gastrointestinal symptoms (8%), myopathy and musculoskeletal pain (up to 7%), and 
rhabdomyolysis, which is rare (0.005%) but serious.13 Adverse effects are more problematic 
in older patients, especially those with metabolic disturbances, kidney or liver compromise, 
or polypharmacy.13–15 From a cost standpoint, value can be enhanced through thoughtful 
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matching of treatments to patients who will benefit. Although an individual may accrue 
some financial benefit, the overall effect of discontinuing medicines on national health care 
spending is inherently a population-based and policy question.
Although there is compelling evidence for prescribing statins for primary or secondary 
prevention for people who are expected to live for many years, no evidence exists to guide 
decisions to discontinue statin therapy in patients with limited prognosis. We conducted this 
randomized trial to evaluate the safety and clinical impact of statin discontinuation in the 
palliative care setting. We hypothesized that there would be no significant difference in 60-
day mortality (primary outcome), cardiovascular events, or performance status and that 
QOL, symptoms, number of medications, and satisfaction with care, as well as reduced cost, 
would be better among patients randomized to discontinue statin therapy.
Methods
Design
This study was a multicenter, parallel-group, unblinded, randomized, pragmatic clinical trial. 
Participants were randomized to either discontinue or continue statin therapy at the time of 
enrollment. The trial protocol is available in the Supplement.
Patients
Eligibility criteria were broad to maximize the generalizability of the findings. Eligible 
patients were English-speaking adults (aged ≥18 years) receiving a statin for 3 months or 
longer for primary or secondary prevention of cardiovascular disease. Eligible patients had a 
documented diagnosis of advanced, life-limiting illness determined by (1) at least 1 
physician indicating he or she “would not be surprised if the patient died in the next 
year,”16–18 (2) life expectancy of more than 1 month, and (3) recent deterioration in 
functional status, with a reduction in the Australia-Modified Karnofsky Performance 
Status19 scale score to less than 80% in the previous 3 months. Study participants were 
either cognitively intact (Short Portable Mental Status Questionnaire20 score of ≤4 of 10) or 
represented by a legally authorized English-speaking person willing and able to provide 
proxy consent and study data. Exclusion criteria were treating physician’s opinion that the 
patient had active cardiovascular disease or sufficient risk of active cardiovascular disease to 
require ongoing therapy with statin medications, symptoms of myositis, liver function test 
(aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase) or creatine 
kinase levels of more than 2.5 times the upper limit of normal, or other contraindications to 
continuing statin therapy. The patient was also excluded if the patient or proxy was 
unwilling or unable to provide informed consent or if the treating physician was unwilling to 
have the patient enrolled. The study was conducted from June 3, 2011, to May 2, 2013.
Patients were enrolled from 15 Palliative Care Research Cooperative Group member sites21 
after relevant institutional review board approval. The patients provided written informed 
consent and received no financial compensation. The full study protocol can be found in the 
trial protocol in the Supplement.
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Block randomization was used to allocate participants to study arms in a 1:1 ratio stratified 
by study site and cardiovascular disease history (yes or no). Block sizes of 2, 4, and 6 were 
randomly generated using SAS, version 9.2 (SAS Institute Inc), and data were maintained in 
a secure central server. Participants were randomized immediately after providing informed 
consent and completing baseline data collection. A secure web-site was used to 
communicate randomization allocation to study site personnel.
End Points
The primary end point of the study was the proportion of deaths within 60 days of trial 
enrollment. In the original protocol, the primary end point was survival; the sample size 
estimate of 1200 participants (600 per group) was based on a projected median overall 
survival of 13 weeks and a 2-week difference in survival. The study was designed with 2 
interim analyses (total of 3 analyses, including the end of the study) using an O’Brien-
Fleming design22 with analysis intervals spaced by equal information time. Partway through 
the trial, the pooled median survival was approximately 9 months (approximately 3 times 
the original survival projections); a resizing calculation estimated a new sample size 
requirement of more than 30 000. Upon recommendation from the study data and safety 
monitoring board, the primary end point was changed to the proportion of deaths within 60 
days of trial enrollment. The consequent revised sample size target was 360 participants; 
plans for further interim analyses were dropped. Although we focused on 60-day mortality 
as the primary outcome, we captured longer-term mortality and other important clinical 
outcomes that provide critical contextual information once the effect on mortality is 
understood.
Secondary end points addressed 2 safety concerns: survival and time to first cardiovascular-
related event, defined as a new cardiovascular event or invasive cardiovascular procedure 
with hospital or emergency department admission. Additional secondary end points 
addressed patient-centered outcomes important in the setting of advanced life-limiting 
illness: performance status, QOL, symptoms, number of nonstatin medications, statin-related 
adverse effects, and satisfaction with health care (assessed by likelihood to recommend 
current health care). With data and safety monitoring board approval, we enrolled more 
participants than the revised sample size target to increase information about secondary end 
points.
Study Procedures and Assessments
Baseline assessment, which was conducted in person by a trained research assistant, 
included demographics, primary diagnosis, comorbid illnesses, Charlson Comorbidity Index 
score,23 the results of the most recent laboratory studies, statin medication history, cognition 
(as measured by the Short Portable Mental Status Questionnaire20), and insurance status. 
Survival, performance status, and health resource utilization data were collected weekly 
during the first month and then monthly until death or 1 year. Patient-reported outcomes (eg, 
QOL, symptoms, and satisfaction) were collected in person or by telephone at weeks 2, 4, 8, 
12, 16, 20, and 24.
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Quality of life was measured with the McGill Quality of Life Questionnaire, reflected by a 
single-item overall QOL score and selected subscales (physical symptom, psychological 
symptom, existential well-being, and support).24,25 A total score was computed as the mean 
of the 4 subscales. If at least half of the items in a subscale were answered, missing values 
were imputed using the mean of the completed items. Scores ranged from 0 to 10, with 
higher scores indicating better QOL.
Symptoms were measured using the Edmonton Symptom Assessment System scale.26 The 9 
standard items on the scale (pain, fatigue, nausea, depression, anxiousness, drowsiness, 
appetite, well-being, and breathing) were supplemented with 4 additional items specific to 
statin use (muscle-related pain, weakness, headache, and fever). Scores were summed from 
the 9 standard items, the 4 supplemental items, and for all 13 items. The same imputation 
rule used for determination of QOL was applied to missing responses. Performance status 
was measured using the Australia-Modified Karnofsky Performance Status scale,19 with 
scores ranging from 0 (death) to 100 (no symptoms, no evidence of disease).
We documented the number of nonstatin medications that were (1) regularly scheduled, (2) 
administered as needed on at least 50% of the days in the prior week, and (3) administered 
as needed on fewer than 50% of days in the prior week. All 3 measures were combined into 
a variable quantifying the total number of nonstatin medications. Satisfaction with care was 
quantified through a question that asked about the likelihood of recommending the current 
health care to others and used a 5-point Likert scale (1, very unlikely to 5, very likely).
Prespecified adverse events monitored at each assessment included hospital admissions, 
emergency department visits, new cardiovascular events, invasive procedures for cardiac 
events, venous thromboembolism, and pneumonia. Ad hoc adverse events were documented 
and monitored by site investigators.
Participants remained in the study until death, 1 year after enrollment, or study closure. If a 
participant wished to withdraw, he or she was given the option for passive data collection 
via medical record review to document survival and health services utilization. If proxy 
response was used, only the following objective data were collected: participant survival 
status, functional status, use of hospice or palliative care, likelihood to recommend the care 
received, prespecified adverse events, adherence to randomization assignment, and, if 
applicable, reason for study withdrawal.
Cost Savings
We estimated the patient-specific monthly cost of the baseline statin therapy using a national 
average retail price (February 2012) compiled by Consumer Reports.27 We measured neither 
out-of-pocket cost nor the amount paid by third-party insurance; an average retail price 
approximates a societal cost. Two authors (T.W.L., S.Y.Z.) adjudicated ambiguous 
information. We estimated the cost savings resulting from statin discontinuation by first 
converting monthly to daily costs and then tracking the avoided costs from the time each 
patient was randomized until death or censorship.
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End points were summarized using routine descriptive statistics. All analyses were 
performed using an intent-to-treat approach. Safety analyses included the primary end point 
(death within 60 days) and time-to-event analyses for secondary end points (time to death 
and time to first cardiovascular-related event); these end points were tested with a 
noninferiority hypothesis, with each end point using a 1-sided α = .05–level test. For these 3 
safety analyses, the established differences to exclude in the noninferiority hypotheses were 
5%, 3 weeks, and 2 weeks, respectively, as determined a priori to be clinically meaningful 
by the study investigators.
For the primary end point, discontinuing statin therapy was considered to be noninferior to 
continuing therapy if the 90% CI for the difference in proportion who died (θ = pdiscontinue − 
pcontinue) ruled out a 0.05 increase in the proportion of deaths for patients who discontinued 
statin therapy compared with those who continued the therapy (ie, the upper limit of the 
90% CI for the difference in proportions is <0.05). A nonparametric log-rank test was used 
to compare time-to-event differences between the 2 study groups.
Patient-centered secondary end points (QOL, symptoms, performance status, number of 
nonstatin medications, and likelihood to recommend the care being given) were measured 
longitudinally at multiple time points. For each analysis, a growth-curve model was fit to the 
data using a piecewise-linear function with knots at 4, 8, and 12 weeks. Each outcome was 
summarized using an area-under-the-curve summary calculated from baseline through week 
20. This 20-week cut point was chosen to maximize use of data while accounting for the fact 
that the amount of data diminished as the study progressed, thereby increasing variability 
and uncertainty of area-under-the-curve estimates when data beyond 20 weeks were 
included. The area under the curve was rescaled so that scores could be interpreted as the 
mean across 20 weeks. Group differences were assessed using a 2-sided α = .05–level test.
Repeated-measures outcomes were analyzed using a mixed-effects model performed with 
maximum-likelihood estimation for incomplete repeated measures. This approach allowed 
all available data to be used in the estimation of model variables and assumed that missing 
data were missing at random. Dropout rates and reasons for dropout were similar between 
study arms.
Results
Of 381 patients enrolled, 189 were randomized to discontinue statin therapy and 192 to 
continue therapy (Figure 1). Median follow-up time was 18 weeks (quartile [Q]1 = 8, Q3 = 
36) for all participants. Follow-up time for participants who died during the study was a 
median of 10 (Q1 = 5, Q3 = 23) weeks.
Participants were generally older, white, and receiving Medicare and had declining 
performance status (Table 1). Approximately half of the participants (48.8%) had cancer as 
their primary diagnosis, 58.0% had cardiovascular disease, and 69.0% had received statins 
for more than 5 years; 36.0% of the patients were enrolled in hospice at study initiation. The 
intervention groups were similar at baseline except for cognitive impairment, with a larger 
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proportion of people who were cognitively impaired randomized to discontinue statin 
therapy (27.0% vs 17.2%; P = .02).
Median and mean survival for the entire study population was 219 and 213 days (31 and 30 
weeks), respectively. The proportion of participants who died within 60 days was not 
significantly different between groups (discontinuation vs continuation, 45 [23.8%] vs 39 
[20.3%]; 90% CI, −3.5% to 10.5%; P = .36). Noninferiority was not achieved because the 
upper confidence limit for the difference in proportion of participants who died within 60 
days (10.5%) exceeded the noninferiority margin of 5%. Survival was similar between the 
groups, with a median time to death for the discontinuation vs continuation groups of 229 
days (90% CI, 186–332) vs 190 days (90% CI, 170–257), respectively (P = .60) (Figure 2). 
There was no significant difference in time to first cardiovascular-related event (P = .64); 
only 24 of the participants (6.3%) experienced a cardiovascular-related event 
(discontinuation, 13; continuation, 11).
Total McGill QOL was significantly higher among the group discontinuing statin therapy 
(mean area under the curve, 7.11 vs 6.85; P = .04) (Table 2, Table 3, and Figure 3 for all 
QOL results). Small differences in QOL subscales were observed, with significant 
differences in the support (P = .005) and well-being (P = .05) domains but not in the 
psychological (P = .06) and physical (P = .64) domains. The single question measuring 
overall QOL demonstrated no significant difference (6.53 vs 6.35; P = .44).
Discontinuing statin therapy had no significant effect on physical symptoms or performance 
status (Table 2). Participants whose therapy was discontinued trended toward lower 
summary 9-item Edmonton Symptom Assessment System scores (25.2 vs 27.4; P = .13). 
There were no significant differences in statin-specific symptoms (muscle-related pain, 
weakness, headache, and fever) (7.0 vs 7.2; P = .71). Longitudinal performance status 
assessment (Australia-Modified Karnofsky Performance Status score) also was not 
significantly different between the groups (47.7 vs 48.5; P = .63).
Although participants in both study arms received many medications, the total number of 
nonstatin agents was significantly lower in the group discontinuing statin therapy by 0.7 
medications (10.1 vs 10.8; P = .03). Cost savings (Table 3) attributable to statin therapy 
discontinuation were $3.37 per day (95% CI, 2.83–3.91) for a mean savings of $716.46 for 
participants with a mean follow-up time of 212.6 days. If all patients had been receiving a 
generic statin formulation at randomization (75% were), daily savings would have been 
$2.96 per day ($629.30 per patient) at the mean follow-up time, representing potential 
savings in the United States of $603 million in 2014.
Most study participants had high satisfaction with their current health care, with 5 as the 
highest possible score (discontinuation, 4.63; continuation, 4.55; P = .22). Adverse events 
were rare, with only 33 experienced by 19 of the participants (5.0%). No serious adverse 
events were determined to be study related.
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In a study population with a median survival of approximately 7 months and primary 
diseases evenly divided between cancer and noncancer diagnoses, it appears that stopping 
statin therapy is safe and potentially associated with benefit, including improved QOL and 
fewer other nonstatin medications combined with a corresponding reduction in medication 
costs.
Scientific and Clinical Context of the Results
More than 80% of Americans are expected to die of chronic illnesses,9 primarily 
cardiovascular disease, cancer, dementia, and chronic lung disease. Clinical trial28 evidence 
supports the use of statins in patients with hyperlipidemia and ischemic heart disease to 
reduce the risk of cardiovascular events and mortality, as well as to reduce the risk of 
cardiovascular events in patients with multiple cardiac risk factors. Beneficial outcomes are 
generally evident after at least 2 years of treatment.29 Given their positive effect on 
morbidity and death, statins are among the most prescribed medications, and this number is 
expanding30; 40% of statins are prescribed for primary prevention of cardiovascular disease, 
and therapy is frequently continued until the end of life.7 The risks and burdens vs benefits 
of statins for patients with a limited prognosis has been a clinical uncertainty.31 Based on 
our study findings, it is reasonable for providers to discuss with patients and their caregivers 
whether to discontinue statins prescribed for primary or secondary prevention of 
cardiovascular disease when advanced illness is consistent with a high risk for death within 
the next 6 to 12 months.
The inability to discern a difference in survival between patients who continue and 
discontinue statin therapy may be related to any of several mechanisms. The effect of statins 
on reducing plaque growth may be more important early in the disease course.32 For patients 
with advanced illness, underlying organ failure (kidney, liver, and heart) potentially offsets 
the beneficial effects of statins even when reductions in low-density lipoprotein levels are 
achieved.28 Indeed, the finding of a decreased survival benefit in sicker patients and a 
greater benefit in healthier patients has been demonstrated in many clinical trials, especially 
among those with heart failure33 or those undergoing dialysis.34 Altered metabolism of 
medications may also partially explain the lack of benefit with statins.35
Recent trials confirm increased average creatine kinase levels and muscle symptoms36 as 
well as reduced strength and exercise tolerance37,38 in patients receiving statins, which can 
worsen in the setting of advancing life-limiting illness. Patients randomized to the 
discontinuation arm showed a significant reduction in the mean number of nonstatin 
medications; it is possible that discontinuing statin therapy reduces the number of adverse 
effects and decreases the need for medications taken to treat those effects.1 Certainly, 
simplification of medicine regimens has important benefits in terms of health, patient and 
caregiver burden, and cost.
Previous observational studies have investigated statin discontinuation with variable results. 
In the systematic review by Gomez Sandoval et al,39 most observational studies did not 
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demonstrate an increase in mortality with statin therapy discontinuation; studies that did 
tended to be in younger populations who appeared less sick than the population we studied.
We included participants in the present study with an advanced life-limiting illness and 
declining functional status; these were patients who would not routinely be expected to live 
longer than 1 year. We chose this population because, based on several large clinical trials, 
benefits from statins are seen at the earliest after 2 years of therapy.29 Given well-
documented evidence40 of benefit over time for primary and secondary prevention of 
cardiovascular disease, our findings should not be generalized beyond the population with 
life-limiting illness and limited prognosis that we studied.
Application: The Case for Patient-Centered Decision Making
Given the uncertain benefit and possible harm of continuing statin therapy among people 
with life-limiting illness and functional decline, patient-centered decision making regarding 
therapy discontinuation is warranted. Patient-centered decision making entails informing 
patients or their proxies about treatment options, including the trade-offs between risks and 
benefits, and incorporating patient preferences when implementing a decision.41,42 This 
approach is appropriate when there is no clearly superior choice and patients’ preferences 
are a key element of making the best choice.43–45 For people with advanced illness, the 
present study provides critical information to inform discussions between physicians and 
patients: “How can we make a decision together about the management of your statin 
medication based on your personal wishes, circumstances, and the evidence?”
For patients with shorter life expectancy, greater concern about pill burden, and more 
comfort-oriented goals of care, physicians may endorse discontinuing statins as a means to 
reduce the number of medications without apparent harmful effects on survival or QOL. 
With symptoms and QOL as the concern, people whose statin therapy was discontinued had 
trends toward improvement in these outcomes (Table 2). For patients who do not want to 
discontinue statin therapy, the data suggest that continuing the medicine is not likely to be 
harmful.
There is an increasing evidence base that discontinuation of some therapies may be 
beneficial for selected patient populations. If the results we report—improved QOL, no 
significant differences in mortality, and modest cost savings—had been produced by a 
randomized clinical trial of a new drug in patients with advanced life-limiting illness, the 
trial would be heralded as a breakthrough and there would be discussion of how to speed 
access to this new drug. The same energy needs to be applied to determining when it is 
appropriate for physicians to discuss discontinuing statin therapy with their patients.
Limitations
Our trial has several important limitations. First, the primary endpoint and target sample size 
were modified midway through the study in collaboration with the data and safety 
monitoring board. Despite these revisions, noninferiority for the primary end point (the 
proportion of participants who died within 60 days) was not achieved. Second, enrolling 
more patients would have increased statistical power for the assessment of the important 
secondary end points; nonetheless, secondary end points trended together with a general 
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pattern in favor of discontinuing statins. Third, this study was a pragmatic trial without 
blinding. Study participants and their physicians knew whether statin therapy was being 
continued or discontinued. In theory, the absence of blinding could bias toward 
identification of more adverse consequences of discontinuing therapy, but this bias was not 
noted. Because the primary treating physician also had to be willing for the patient to be 
randomized, this factor may have biased the findings toward those in whom it may have 
been safer to discontinue statins. Fourth, patients who enrolled were those willing to be 
randomized to statin therapy discontinuation. Not all patients with limited prognosis would 
be willing to consider discontinuing therapy. Fifth, application of the trial results requires 
prognostication, which is difficult, as evidenced by the difference between the anticipated 
survival at the outset of the study and the observed survival. Nonetheless, the application of 
routine criteria helped to define a population of seriously ill individuals with a median 
survival of 7 months. Sixth, we do not know how much a patient paid for a prescription vs 
what their insurance company paid or what proportion of patients nationwide who have a 
limited prognosis and are taking a statin could clinically discontinue their statin therapy. 
Finally, the participants discontinuing statin therapy were more likely to be cognitively 
impaired, which most likely dampened positive findings in favor of discontinuing the 
medication by biasing the study toward more deaths and fewer available patient-reported 
data.
Conclusions
To the extent possible, evidence should inform decisions to initiate, continue, and 
discontinue medication therapy. This study provides evidence that suggests that survival is 
not affected when statins prescribed for primary or secondary prevention of cardiovascular 
disease are discontinued in this population. Although the cost savings identified were 
modest, the data suggest that statin therapy discontinuation in selected patients may improve 
QOL at reduced aggregate health care cost. The strengths of this study are its pragmatic 
design and conduct in multiple clinical settings with recruitment of a population that is 
representative of the broad range of life-limiting diagnoses encountered in clinical practice. 
These aspects of the study enhance the generalizability and applicability of its findings to 
real-world clinical practice. Given the value and symbolism that patients may ascribe to 
preventive chronic medications and the importance of prognosis in timing this decision, the 
choice to continue or stop therapy with statin medications merits patient-centered decision 
making between the physician and the patient. Additional research exploring the use of other 
medications (eg, anticoagulants, antihypertensives, or oral hypoglycemics) in populations 
with limited life expectancies is needed.
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Figure 1. CONSORT Flow Diagram
A total of 189 patients were randomized to discontinue statin therapy and 192 were 
randomized to continue therapy.
aContraindications to continuing or discontinuing statin therapy.
bDistribution of withdrawals between study arms; P= .85.
cDistribution of outcomes between study arms; P= .58.
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Figure 2. Product-Limit Survival Estimates
The 90% confidence bands are indicated. Light gray shading indicates the 90% confidence 
bands for the continuation arm of the study; light brown shading, the 90% confidence bands 
for the discontinuation arm of the study.
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Figure 3. Summary of Patient-Reported Outcomes
In this visual summary of Table 3, the estimates and 95% CIs are presented using 
standardized units so that the CI widths are comparable; results favoring discontinuation of 
statin therapy are aligned on the left side of zero. The numeric estimates and 95% CIs are 
presented in the units of the actual analyses, thereby aligning with Table 3. AKPS indicates 
Australia-Modified Karnofsky Performance Status; PRN, administered as needed.
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P ValueDiscontinued Statin (n = 189) Continued Statin (n = 192) Total (N = 381)
Age, mean (SD), y 74.8 (11.7) 73.5 (11.5) 74.1 (11.6) .29
Sex
 Male 98 (51.9) 112 (58.3) 210 (55.1)
.20
 Female 91 (48.1) 80 (41.7) 171 (44.9)
Race
 White 153 (81.0) 162 (84.4) 315 (82.7)
.30
 Black 32 (16.9) 22 (11.5) 54 (14.2)
 Other 3 (1.6) 7 (3.6) 10 (2.6)
 Multiple 1 (0.5) 1 (0.5) 2 (0.5)
Ethnicity
 Hispanic 6 (3.2) 10 (5.2) 16 (4.2)
.32 Non-Hispanic 182 (96.3) 181 (94.3) 363 (95.3)
 Unknown 1 (0.5) 1 (0.5) 2 (0.5)
Educational level
 <High school 27 (14.3) 24 (12.5) 51 (13.4)
.63
 High school graduate 100 (52.9) 95 (49.5) 195 (51.2)
 College graduate 61 (32.3) 70 (36.5) 131 (34.4)
 Unknown 1 (0.5) 3 (1.6) 4 (1.0)
Insurance
 Medicare 140 (74.1) 140 (72.9) 280 (73.5)
.34
 Medicaid 18 (9.5) 16 (8.3) 34 (8.9)
 Private 23 (12.2) 20 (1.4) 43 (11.3)
 Other 8 (4.2) 13 (6.8) 21 (5.5)
 Uninsured 0 3 (1.6) 3 (0.8)
History of cardiovascular disease
 Yes 111 (58.7) 110 (57.3) 221 (58.0)
.78
 No 78 (41.3) 82 (42.7) 160 (42.0)
Statin use, y
 <1 4 (2.1) 2 (1.0) 6 (1.6)
.69
 1–5 50 (26.5) 51 (26.6) 101 (26.5)
 >5 129 (68.3) 134 (69.8) 263 (69.0)
 Unknown 6 (3.2) 5 (2.6) 11 (2.9)
Primary diagnosis
 Malignant tumor 84 (44.4) 102 (53.1) 186 (48.8)
.09
 Other 105 (55.6) 90 (46.9) 195 (51.2)
Charlson Comorbidity Index score, mean (SD) 4.8 (2.9) 4.9 (2.7) 4.9 (2.8) .67
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Variable
No. (%)
P ValueDiscontinued Statin (n = 189) Continued Statin (n = 192) Total (N = 381)
AKPS score, mean (SD) 52.4 (13.2) 54.5 (12.8) 53.5 (13.0) .13
Cognitively impaired
 Yes 51 (27.0) 33 (17.2) 84 (22.0)
.02
 No 138 (73.0) 159 (82.8) 297 (78.0)
Enrolled in hospice
 Yes 63 (33.3) 74 (38.5) 137 (36.0)
.27 No 124 (65.6) 115 (59.9) 239 (62.7)
 Unknown 2 (1.1) 3 (1.6) 5 (1.3)
Nonstatin medications, mean (SD) 11.6 (5.1) 11.5 (4.9) 11.6 (5.0) .84
Abbreviation: AKPS, Australia-Modified Karnofsky Performance Status.
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Table 3
Cost Savings Associated With Statin Therapy Discontinuationa
Variable
Cost Savings, $
Prescribed Generic Formulation Only
Mean survival, d 212.6 212.6
Mean saved per patient
 Days 3.37 2.96
 During mean lifespan in this trial 716.46 629.30
Projected annual US savings
 2014 Population, million 603 529
 2040 Population, billion 1 879
a
Cost calculated using 2012 US dollars.
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